Sign in

CIK 0001563880

  • Non-accelerated filer
  • Smaller reporting company

Trevi Therapeutics, Inc.

Sign in to watch
Ticker
TRVI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
450834299
Phone
+1 203-304-2499
Business address
195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Exercise or conversion Chief Financial Officer acquired 6,000 shares (option exercise)
  7. 4 Exercise or conversion Galletta Christopher acquired 15,000 shares (option exercise)
  8. 4 Derivatives Options or other derivatives
  9. 4 Open-market sale President & CEO sold 6,059 shares at an average $3.03 ($18,371)
  10. 4 Open-market sale President & CEO sold 55,121 shares at an average $3.09 ($170,193)
  11. 4 Open-market sale Director sold 4,555 shares at $2.93 ($13,353)
  12. 4 Open-market sale Chief Scientific Officer sold 16,496 shares at $2.96 ($48,883)
  13. 4 Open-market sale Chief Scientific Officer sold 31,505 shares at an average $2.77 ($87,228)
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market sale Chief Scientific Officer sold 53,368 shares at $2.55 ($136,110)

Page 3 of 13 · 257 filings